Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2020 Mar 12;40(5):1256–1274. doi: 10.1161/ATVBAHA.120.314147

Figure 4. While CDC6 and IL-33 expression are required for both HASMC and MASMC proliferation and migration, respectively, LMCD1 exhibits differential effects on their expression between human and mice.

Figure 4.

A-D. Quiescent HASMCs (A & C) or MASMCs (B & D) were treated with and without thrombin (0.5 u/ml) for the indicated time periods, cell extracts were prepared and analyzed by Western blotting for CDC6, IL-33 and β-actin levels using their specific antibodies. E-H. HASMCs (E & G) or MASMCs (F & H) that were transfected with siControl or siCDC6 (100 nM) or preincubated with IgG or neutralizing IL-33 antibody (100 ng/ml) were quiesced and tested for thrombin (0.5 U/ml)-induced DNA synthesis (E & F) or migration (G & H). HASMCs (I & K) or MASMCs (J & L) that were transfected with siControl or siLMCD1 (100 nM) and quiesced were treated with and without thrombin (0.5 U/ml) for 8 hrs, cell extracts were prepared and analyzed by Western blotting for CDC6, IL-33 and β-actin levels using their specific antibodies. The same membranes were also reprobed for LMCD1 levels to show its siRNA efficacy. The bar graphs represent the Mean ± S.D. values of three independent experiments. *, p < 0.05 versus siControl + vehicle; **, p < 0.05 versus siControl + Thrombin.